For this reason, you should always build for differentiation: Create proprietary systems around adherence tracking, behavioral reinforcement, or personalized data models
These data are limited and uncontrolled, so they should guide, not guarantee, expectations
To view or add a comment, sign in GLP-1 Drugs: My Take as a Pharmacist Every week, I see articles warning about the dangers of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro
Specifically, Ubx modulates co-transcriptional splicing through its DNA binding ability and interplay with active RNA Polymerase II (Pol II) 21
The SUMMIT trial (Packer et al, NEJM 2025) randomized 731 patients with HFpEF and obesity (mean BMI 38) to tirzepatide vs
The combination shows approximately 15-18% weight loss, falling between semaglutide alone and tirzepatide